A Phase 1 Study of S-3304 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Registration Number
- NCT00033215
- Lead Sponsor
- Shionogi
- Brief Summary
To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
University of Colorado Hospital
🇺🇸Denver, Colorado, United States
H. Lee Moffitt Concer Center and Research Institute
🇺🇸Tampa, Florida, United States
Roswell Park Cancer Center
🇺🇸Buffalo, New York, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
University of Colorado Hospital🇺🇸Denver, Colorado, United States